Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;47(1):47-58.
doi: 10.1007/s40618-023-02121-4. Epub 2023 Jun 16.

Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta

W-B Zheng  1   2 , J Hu  1 , L Sun  1 , J-Y Liu  1 , Q Zhang  1 , O Wang  1 , Y Jiang  1 , W-B Xia  1 , X-P Xing  1 , M Li  3
Affiliations

Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta

W-B Zheng et al. J Endocrinol Invest. 2024 Jan.

Abstract

Purpose: Lipocalin 2 (LCN2) is a newly recognized bone-derived factor that is important in regulation of energy metabolism. We investigated the correlation of serum LCN2 levels and glycolipid metabolism, and body composition in a large cohort of patients with osteogenesis imperfecta (OI).

Methods: A total of 204 children with OI and 66 age- and gender-matched healthy children were included. Circulating levels of LCN2 and osteocalcin were measured by enzyme-linked immunosorbent assay. Serum levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), and low- and high-density lipoprotein cholesterol (LDL-C, HDL-C) were measured by automated chemical analyzers. The body composition was measured by dual-energy X-ray absorptiometry. Grip strength and timed-up-and-go (TUG) were tested to evaluate the muscle function.

Results: Serum LCN2 levels were 37.65 ± 23.48 ng/ml in OI children, which was significantly lower than those in healthy control (69.18 ± 35.43 ng/ml, P < 0.001). Body mass index (BMI) and serum FBG level were significantly higher and HDL-C levels were lower in OI children than healthy control (all P < 0.01). Grip strength was significantly lower (P < 0.05), and the TUG was significantly longer in OI patients than healthy control (P < 0.05). Serum LCN2 level was negatively correlated to BMI, FBG, HOMA-IR, HOMA-β, total body, and trunk fat mass percentage, and positively correlated to total body and appendicular lean mass percentage (all P < 0.05).

Conclusions: Insulin resistance, hyperglycemia, obesity, and muscle dysfunction are common in OI patients. As a novel osteogenic cytokine, LCN2 deficiency may be relevant to disorders of glucose and lipid metabolism, and dysfunction of muscle in OI patients.

Keywords: Body composition; Glycolipid metabolism; Lipocalin 2; Muscle function; Osteogenesis imperfecta.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Serum LCN2 levels with different clinical and genotypic classifications of OI children. a Serum LCN2 levels with different clinical severity of OI children. b Serum LCN2 levels with different genotypes of OI children. *P < 0.05
Fig. 2
Fig. 2
Correlation of serum LCN2 levels and glucose metabolic parameters in OI children. a Correlation of serum LCN2 levels and fasting blood glucose (FBG) in OI children. b Correlation of serum LCN2 levels and body mass index (BMI) in OI children. c Correlation of serum LCN2 levels and HOMA-IR in OI children. d Correlation of serum LCN2 levels and HOMA-β in OI children
Fig. 3
Fig. 3
Muscle strength and function in OI children and healthy controls. a Grip strength in OI children and healthy controls. b Timed-up-and-go (TUG) test in OI children and healthy controls. *P < 0.05
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mosialou I, Shikhel S, Liu JM, Maurizi A, Luo N, He Z, Huang Y, Zong H, Friedman RA, Barasch J, Lanzano P, Deng L, Leibel RL, Rubin M, Nickolas T, Chung W, Zeltser LM, Williams KW, Pessin JE, Kousteni S. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature. 2017;543(7645):385–390. doi: 10.1038/nature21697. - DOI - PMC - PubMed
    1. Mosialou I, Shikhel S, Luo N, Petropoulou PI, Panitsas K, Bisikirska B, Rothman NJ, Tenta R, Cariou B, Wargny M, Sornay-Rendu E, Nickolas T, Rubin M, Confavreux CB, Kousteni S. Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes. J Exp Med. 2020 doi: 10.1084/jem.20191261. - DOI - PMC - PubMed
    1. Tournis S, Dede AD. Osteogenesis imperfecta—a clinical update. Metabolism. 2018;80:27–37. doi: 10.1016/j.metabol.2017.06.001. - DOI - PubMed
    1. Marom R, Rabenhorst BM, Morello R. Osteogenesis imperfecta: an update on clinical features and therapies. Eur J Endocrinol. 2020;183(4):R95–r106. doi: 10.1530/eje-20-0299. - DOI - PMC - PubMed
    1. Chetty M, Roomaney IA, Beighton P. The evolution of the nosology of osteogenesis imperfecta. Clin Genet. 2021;99(1):42–52. doi: 10.1111/cge.13846. - DOI - PubMed